Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지
DOI QR코드

DOI QR Code

Updates of Chemotherapy for Pancreatic Cancer

췌장암 항암화학요법의 최신 지견

  • Min Je Sung (Department of Gastroenterology, CHA Bundang Medical Center, CHA University)
  • 성민제 (차의과학대학교 분당차병원 소화기내과)
  • Received : 2023.11.29
  • Accepted : 2023.12.08
  • Published : 2023.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

Pancreatic cancer is one of the most aggressive cancers, and it is expected to become the second-leading cause of cancer-related death in the United States by 2030. Its 5-year survival rate is <10% and approximately 15% of cases are eligible for surgical treatment during diagnosis. Furthermore, the risk of recurrence within 1 year postoperative is as high as 50%. Therefore, chemotherapy plays a crucial role in pancreatic cancer treatment. Survival rates are speculated to have improved since the introduction of FOLFIRINOX and gemcitabine/nab-paclitaxel combination therapy for metastatic pancreatic cancer in the 2010s. Additionally, the implementation of both neoadjuvant and adjuvant treatments in resectable and borderline resectable pancreatic cancer caused better outcomes compared to upfront surgery. Recently, not only have these medications advanced in development, but so have PARP inhibitors and KRAS inhibitors, contributing to the treatment landscape. This study aimed to explore the latest insights into chemotherapy for pancreatic cancer.

Keywords

References

  1. Jung KW, Won YJ, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat 2019;51:417-430. https://doi.org/10.4143/crt.2019.138
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34. https://doi.org/10.3322/caac.21551
  3. Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2016. 2019. https://seer.cancer.gov/archive/csr/1975_2016/results_merged/sect_01_overview.pdf (accessed November 17, 2023).
  4. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-2921. https://doi.org/10.1158/0008-5472. CAN-14-0155 Erratum in: Cancer Res 2014;74:4006.
  5. Kleeff J, Reiser C, Hinz U, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 2007;245:566-572. https://doi.org/10.1097/01.sla.0000245845.06772.7d
  6. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310:1473-1481. https://doi.org/10.1001/jama.2013.279201
  7. Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008;247:456-462. https://doi.org/10.1097/SLA.0b013e3181613142
  8. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2009;35:600-604. https://doi.org/10.1016/j.ejso.2008.12.006
  9. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825. https://doi.org/10.1056/NEJMoa1011923
  10. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-1703. https://doi.org/10.1056/NEJMoa1304369
  11. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903. https://doi.org/10.1001/archsurg.1985.01390320023003 Erratum in: Arch Surg 1986;121:1045.
  12. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987;59:2006-2010. https://doi.org/10.1002/1097-0142(19870615)59:12<2006::aid-cncr2820591206>3.0.co;2-b
  13. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210. https://doi.org/10.1056/NEJMoa032295 Erratum in: N Engl J Med 2004;351:726.
  14. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-277. https://doi.org/10.1001/jama.297.3.267
  15. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-1081. https://doi.org/10.1001/jama.2010.1275
  16. Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016;388:248-257. https://doi.org/10.1016/S0140-6736(16)30583-9
  17. Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 2014;32:504-512. https://doi.org/10.1200/JCO.2013.50.7657
  18. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:1011-1024. https://doi.org/10.1016/S0140-6736(16)32409-6
  19. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018;379:2395-2406. https://doi.org/10.1056/NEJMoa1809775
  20. Tempero M, O'Reilly E, Van Cutsem E, et al. LBA1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): updated 5-year overall survival. Ann Oncol 2021;32(Suppl 3):S226. https://doi.org/10.1016/j.annonc.2021.06.009
  21. Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 2021;7:421-427. https://doi.org/10.1001/jamaoncol.2020.7328 Erratum in: JAMA Oncol 2021:e215278. https://doi.org/10.1001/jamaoncol.2021.5278
  22. Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007;14:2088-2096. https://doi.org/10.1245/s10434-007-9384-x
  23. O'Reilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 2014;260:142-148. https://doi.org/10.1097/SLA.0000000000000251
  24. Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol 2015;191:7-16. https://doi.org/10.1007/s00066-014-0737-7
  25. Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg 2015;19:1802-1812. https://doi.org/10.1007/s11605-015-2890-4
  26. Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 2017;35:515-522. https://doi.org/10.1200/JCO.2016.68.5081
  27. Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol 2023;34:91-100. https://doi.org/10.1016/j.annonc.2022.09.161
  28. Schwarz L, Bachet, JB, Meurisse A, et al. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN) OX-based chemotherapy: a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). Am Soc Clin Oncol 2022;40(16 Suppl):4134. https://doi.org/10.1200/JCO.2022.40.16_suppl.4134
  29. Labori KJ, Bratlie SO, Biorserud C, et al. Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: a multicenter randomized phase-II trial (NORPACT-1). J Clin Oncol 2023;41(17 Suppl):LBA4005-LBA. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA4005
  30. Chawla A, Shi Q, Ko AH, et al. Alliance A021806: a phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer. J Clin Oncol 2023;41(16 Suppl):TPS4204-TPS. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS4204
  31. van Dam JL, Verkolf EMM, Dekker EN, et al. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. BMC Cancer 2023;23:728. https://doi.org/10.1186/s12885-023-11141-5
  32. Janssen QP, van Dam JL, Bonsing BA, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 2021;21:300. https://doi.org/10.1186/s12885-021-08031-z
  33. Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol 2020;38:1763-1773. https://doi.org/10.1200/JCO.19.02274
  34. Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: longterm results of the Dutch randomized PREOPANC trial. J Clin Oncol 2022;40:1220-1230. https://doi.org/10.1200/JCO.21.02233
  35. Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2023;8:157-168. https://doi.org/10.1016/S2468-1253(22)00348-X
  36. Yamaguchi J, Yokoyama Y, Fujii T, et al. Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01). Ann Surg 2022;275:1043-1049. https://doi.org/10.1097/SLA.0000000000005430
  37. Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol 2022;8:1263-1270. https://doi.org/10.1001/jamaoncol.2022.2319
  38. Kim SS, Nakakura EK, Wang ZJ, et al. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: is radiation necessary in the modern era of chemotherapy? J Surg Oncol 2016;114:587-596. https://doi.org/10.1002/jso.24375
  39. Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 2014;19:266-274. https://doi.org/10.1634/theoncologist.2013-0273
  40. Tinchon C, Hubmann E, Pichler A, et al. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol 2013;52:1231-1233. https://doi.org/10.3109/0284186X.2013.771821
  41. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413. https://doi.org/10.1200/JCO.1997.15.6.2403
  42. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966. https://doi.org/10.1200/JCO.2006.07.9525 Corrected and republished in: J Clin Onco. 2023;41:4714-4720. https://doi.org/10.1200/JCO.22.02770
  43. Cho IR, Kang H, Jo JH, et al. Efficacy and treatmentrelated adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: a single-center cohort study. Semin Oncol 2017;44:420-427. https://doi.org/10.1053/j.seminoncol.2018.01.001
  44. Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 2023;402:1272-1281. https://doi.org/10.1016/S0140-6736(23)01366-1
  45. National Comprehensive Cancer Network. Pancreatic cancer (version 2). 2023. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf (accessed June 19, 2023)
  46. Perri G, Prakash L, Qiao W, et al. Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma. JAMA Surg 2020;155:832-839. https://doi.org/10.1001/jamasurg.2020.2286
  47. Klein-Brill A, Amar-Farkash S, Lawrence G, Collisson EA, Aran D. Comparison of FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma. JAMA Netw Open 2022;5:e2216199. https://doi.org/10.1001/jamanetworkopen.2022.16199
  48. Cho IR, Kang H, Jo JH, et al. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: single-center cohort study. World J Gastrointest Oncol 2020;12:182-194. https://doi.org/10.4251/wjgo.v12.i2.182
  49. Lee JE, Lee HS, Chung MJ, et al. Analysis of clinical predictive factors affecting the outcome of second-line chemotherapy for gemcitabine-refractory advanced pancreatic cancer. Gut Liver 2020;14:135-143. https://doi.org/10.5009/gnl18419
  50. Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014;32:2423-2429. https://doi.org/10.1200/JCO.2013.53.6995
  51. Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011;80:301-306. https://doi.org/10.1159/000329803
  52. Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabinebased therapy (NAPOLI-1): a global, randomised, openlabel, phase 3 trial. Lancet 2016;387:545-557. https://doi.org/10.1016/S0140-6736(15)00986-1 Erratum in: Lancet 2016;387:536. https://doi.org/10.1016/S0140-6736(15)01306-9
  53. Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 2019;108:78-87. https://doi.org/10.1016/j.ejca.2018.12.007
  54. Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015;518:495-501. https://doi.org/10.1038/nature14169
  55. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317-327. https://doi.org/10.1056/NEJMoa1903387
  56. Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology 2022;163:386-402.e1. https://doi.org/10.1053/j.gastro.2022.03.056
  57. Cloyd JM, Katz MHG, Wang H, Cuddy A, You YN. Clinical and genetic implications of DNA mismatch repair deficiency in patients with pancreatic ductal adenocarcinoma. JAMA Surg 2017;152:1086-1088. https://doi.org/10.1001/jamasurg.2017.2631
  58. Riazy M, Kalloger SE, Sheffield BS, et al. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Mod Pathol 2015;28:1383-1389. https://doi.org/10.1038/modpathol.2015.89
  59. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409-413. https://doi.org/10.1126/science.aan6733
  60. Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med 2015;373:1490-1492. https://doi.org/10.1056/NEJMp1510079
  61. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-2520. https://doi.org/10.1056/NEJMoa1500596
  62. Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med 2023;388:33-43. https://doi.org/10.1056/NEJMoa2208470
  63. Bekaii-Saab TS, Spira AI, Yaeger R, et al. KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. J Clin Oncol 2022;40(4 Suppl):519. https://doi.org/10.1200/JCO.2022.40.4_suppl.519
  64. Hofmann MH, Gerlach D, Misale S, Petronczki M, Kraut N. Expanding the reach of precision oncology by drugging All KRAS mutants. Cancer Discov 2022;12:924-937. https://doi.org/10.1158/2159-8290.CD-21-1331